(3.238.7.202) 您好!臺灣時間:2021/03/02 00:19
字體大小: 字級放大   字級縮小   預設字形  
回查詢結果

詳目顯示:::

我願授權國圖
: 
twitterline
研究生:許博翔
研究生(外文):Hsu Po Hsiang
論文名稱:經由一氧化氮所媒介的血管舒張作用在高胰島素血症誘發之高血壓中扮演的角色
論文名稱(外文):The Role of Nitric Oxide-Mediated Vasodilatation in Hyperinsulinemia-Induced Hypertension
指導教授:何橈通何橈通引用關係
指導教授(外文):Ho Low Tone
學位類別:碩士
校院名稱:國立陽明大學
系所名稱:生理學研究所
學門:醫藥衛生學門
學類:醫學學類
論文種類:學術論文
論文出版年:2000
畢業學年度:89
語文別:中文
論文頁數:58
中文關鍵詞:高胰島素血症胰島素阻抗一氧化氮滲透性小膠囊尾部環帶充氣法乙醯膽鹼脂肪細胞
外文關鍵詞:HyperinsulinemiaInsulin resistanceNitric oxideMini osmotic pumpTail-cuff methodAcetylcholineAdipocyte
相關次數:
  • 被引用被引用:0
  • 點閱點閱:103
  • 評分評分:系統版面圖檔系統版面圖檔系統版面圖檔系統版面圖檔系統版面圖檔
  • 下載下載:0
  • 收藏至我的研究室書目清單書目收藏:0
在許多代謝異常的現象,包括高胰島素血症(Hyperinsulinemia)、胰島素阻抗(Insulin resistance)及肥胖等,常伴隨著高血壓一併發生。Reaven將上述這群密不可分且經常同時存在之危險因子統稱為「X症候群(Syndrome X)」。在臨床報告中發現伴隨有高胰島素血症或胰島素阻抗之高血壓病患,其血漿中內皮素-1的濃度均較正常人為高。在過去活體與離體的研究報告中指出,胰島素的確可以增加內皮素的製造及分泌。一氧化氮是一種強力的血管舒張物質,在過去的離體研究報告中指出,細胞中的一氧化氮會受胰島素的刺激而增加,又有離體血管的研究報告指出,在高血壓的情形下,血管舒張方面是受損的。因此,本實驗的目的便是在探討以外源性胰島素誘發高胰島素血症合併高血壓之大白鼠實驗模式中,一氧化氮在血管舒張方面所扮演的角色。在本實驗中,所使用的實驗動物為大白鼠。透過包埋在雄性Sprague-Dawley大白鼠背部皮下的滲透性小膠囊,分別對大白鼠進行人體胰島素(1 unit/rat/day)或生理食鹽水的灌注。來觀察大白鼠體內胰島素的濃度及血壓的變化。血漿中胰島素濃度是利用放射性免疫分析法測得,大白鼠的心跳、收縮壓、平均動脈壓及舒張壓則是利用尾部環帶充氣法(Tail-cuff method)進行監控。實驗進行到第二週控制組大白鼠之血壓開始上升,至五~七週始達到高穩定態,於第八週進行麻醉插管的實驗。分別由靜脈注射不同濃度的乙醯膽鹼(Acetylcholine 0.1、0.3、0.5、1、3、5mg/kg)以及一氧化氮的抑制劑L-NAME(75mg/kg),由接在動脈上的多功能記錄儀觀察其血壓的變化。實驗結果發現,在胰島素灌注八週後,乙醯膽鹼對於血壓下降的作用,相較於對照組有變差的情形。而給予了L-NAME之後,平均動脈壓之變化值又較對照組高。在離體的脂肪細胞實驗中,發現在胰島素灌注大白鼠之脂肪細胞上,胰島素所促進之2-去氧葡萄糖被吸收的能力有下降的情形,且在胰島素受器競爭結合的實驗中,胰島素與受器的結合力明顯較對照組之脂肪細胞差。說明了在這個高血壓的動物模式中伴隨有胰島素阻抗的現象存在。由上述結果顯示,在外源性胰島素灌注的大白鼠動物模式中,造成之高血壓伴隨有高胰島素血症及胰島素阻抗之現象,而經由乙醯膽鹼降血壓的能力受損,L-NAME造成平均動脈壓的升高量較對照組大,間接證明在高血壓時血液中一氧化氮增加量較為顯著,因此在這一類高血壓中,一氧化氮可能扮演著一種保護的角色。

Endothelium constitutes the inner lining of all blood vessels, not simply as a barrier between the blood-stream and the vascular smooth muscle, but also as a modulator of the vascular function. Endothelial cells have been shown to generate nitric oxide (NO), a vasodilator, and endothelin-1 (ET-1), a potent vasoconstrictor. The balance between ET-1 and NO may play an important role in blood pressure regulation. Previous studies found that ET receptor antagonist blunts hyperinsulinemia-induced hypertension in rats. However the role of NO in this model has not been defined. The purpose of my proposed study is to evaluate the changes of NO-mediated vasodilatation in insulin-induced hypertensive rats. Male Sprague-Dawley rats initially weighing 250-300g will be used for the experiments. Human insulin (1 unit/day) or saline will be infused into rats via subcutaneously implanted osmotic minipumps for 8 weeks. The systolic blood pressure, mean blood pressure, diastolic blood pressure and heart rate will be measured twice a week by tail-cuff method. Plasma level of insulin will be measured by radioimmunoassay(RIA) and glucose by glucose analyzer. The first purpose of this study were to test exogenous insulin infusion can induce hyperinsulinemia, insulin resistance and hypertension in rats. The second purpose were to measure the insulin binding activity and to evaluate the ability of glucose uptake in adipocytes isolated from insulin-infused rats and normal rats. After rats develop hypertension, acetylcholine will be administrated to measure the NO-mediated vasodilatation in vivo. There were significant differences in insulin binding and glucose uptake experiment between two groups. After NO inhibitor (L-NAME) intravenous administration, the DMBP in insulin-infusion group were higher than control. The dose response curve of acetylcholine was significant difference in two groups. In conclusion, chronic exogenous insulin infusion induces hyperinsulinemia, insulin resistance and hypertension. The results indicate that the reducing blood pressure ability of acetylcholine was impaired in insulin infusion rats and NO may play a protective role in hyperinsulinemia-induced hypertension.

中文摘要…………………………………………………………… 1
緒論………………………………………………………………… 3
實驗目的…………………………………………………………… 6
材料與方法………………………………………………………… 7
結果………………………………………………………………… 18
討論………………………………………………………………… 24
結論………………………………………………………………… 30
參考文獻…………………………………………………………… 31
附圖1~11

1. Arai H, Hori S, Aramori I, Ohkubo H, Nakanishi S: Cloning
and expression of cDNA encoding and endothelin receptor.
Nature. 1990;348:730-732.
2. Baillie GM, Sherer JT, Weart CW: Insulin and coronary artery
disease: is syndrome X the unifying hypothesis? Ann
Pharmacother. 1998;32:233-247.
3. BergerJ, Biswas C, Vicario PP, Strout HV, Saperstein R,
Pilch PF: Decreased expression of the insulin-responsive
glucose transporter in diabetes and fasting. Nature.
1989;340:70-72.
4. Bonora E, Willeit J, Egger G, Targher G, Bonadonna RC,
Muggeo M: Prevalence of insulin resistance in metabolic
disorders. Diabetes. 1998;47:1643-1649.
5. Bursztyn M, Ben-Ishay D, Mekler J, Raz I: Chronic exogenous
hyperinsulinemia accelerates the development of hypertension
in spontaneously hypertensive rats. Clin Exp Pharmacol
Physiol.1998;1(suppl):S28-S29.
6. Cardillo C, Nambe SS, Choucair WK, Katz A, Quon MJ, Panza
JA: Insulin stimulates both endothelin and nitric oxide
activity in the human forearm. Circulation. 1999;100:820-
825.
7. Cheatham B, Kahn CR: Insulin action and the insulin
signaling network. Endocr Rev. 1995;16:117-142.
8. Chou YC, Perng JC, Juan CC, Jang SY, Kwok CF, Chen WL, Fong
JC, Ho LT: Endothelin-1 inhibits insulin-stimulated glucose
uptake in isolated rat adipocytes. Biochem Biophys Res
Commun. 1994;2002:688-693.
9. Davenport AP, Nunez DJ, Hall JA, Kaumann AJ, Brown MJ:
Autoradiographical localization of binding sites for porcine
[125I]endothelin-1 in humans, pigs, and rats: functional
relevance in humans. J Cardiovasc Pharmacol. 1989;13(suppl
5):S166-S170.
10.Feener EF, King GL: Vascular dysfunction in diabetes
mellitus. Lancet. 1997;350(suppl I):9-13.
11.Garvey WT, Olefsky JM, Matthaei S, Marshall S: Glucose and
insulin co-regulate the glucose transport system in primary
cultured adipocytes. A new mechanism of insulin resistance.
J Biol Chem. 1987;262:189-197.
12.Hopfner RL, Hasnadka RV, Wilson TW, Mcneill JR,
Gopalakrishnan V: Insulin increases endothelin-1-evoked
intracellular free calcium responses by increased ETA
receptor expression in rat aortic smooth muscle cells.
Diabetes. 1998;47:937-944.
13.Huang WC, Fang TC: Angiotensin receptor blockade blunts
hyperinsulinemia-induced hypertension in rats. Hypertension.
1998;32:235-242.
14.Jiang ZY, Zhou QL, Feener EF, White MF, King GL: Endothelin-
1 modulates insulin signaling through phosphatdylinositol 3-
kinase pathway in vascular smooth muscle cells. Diabetes.
1999;48:1120-1130.
15.Juan CC, Fang VS, Huang YJ, Kwok CF, Hsu YP, Ho LT:
Endothelin-1 induces insulin resistance in conscious rats.
Biochem Biophys Res Commun. 1996;227:694-699.
16.Juan CC, Fang VS, Kowk CF, Perng JC, Chou YC, Ho LT:
Exogenous hyperinsulinemia causes insulin resistance,
hyperendothelinemia, and subsequent hypertension in rats.
Metabolism. 1999;227:694-699.
17.Kahn CR, Baird KL, Flier JS, Grunfeld C, Harmon JT, Harrison
LC, Karlsson FA, Kasuga M, King GL, Lang UC, Podskalny JM,
VanObberghen E: Insulin receptors, receptor antibodies, and
the mechanism of insulin action. Recent Prog Horm Res.
1981;37:477-538.
18.Kahn CR, White MF: The insulinreceptor and the molecular
mechanism of insulin action. J Clin Invest. 1988;82:1151-
1156.
19.Kahn CR: Insulin action, diabetogenes, and the cause of type
II diabetes. Diabetes. 1994;43:1066-1084.
20.Kahn CR: Insulin resistance, insulin insensitivity, and
insulin unresponsiveness: a necessary distinction.
Metabolism. 1978;27:1893-1902.
21.Katakam PVG, Ujhelyi MR, Hoenig M, Miller AW: Metformin
improves vascular function in insulin-resistance rats.
Hypertension. 2000;35:108-112.
22.King GL, Goodman D, Buzney S, Moses A, Kahn CR: Receptors
and growth-promoting effects of insulin and insulin-like
growth factors on cells from bovine retinal capillaries and
aorta. J Clin Invest. 1996;71:1167-1176.
23.Kuboki K, Jiang ZY, Takahara N, Ha SW, Igarashi M, Yamauchi
T, Feener EF, Herbert TP, Rhodes CJ, King GL: Regulation of
endothelial constitutive nitric oxide synthase gene
expression in endothelial cells and in vivo. Circulation.
2000;101: 676-681.
24.Meehan WP, Buchanan TA, Hsueh W: Chronic insulin
administration elevates blood pressure in rats.
Hypertension. 1994;23(pt 2):1012-1017.
25.Miller AW, Katakam PVG, Ujhelyi MR: Impaired endothelium-
mediated relaxation in coronary arteries from insulin-
resistant rats. J Vasc Res. 1999;36:385-392.
26.Mitsutomi N, Akashi C, Odagiri J, Matsumura Y: Effects of
endogenous and exogenous nitric oxide on endothelin-1
production in cultured vascular endothelial cells. European
Journal of pharmacology. 1999;364:65-73.
27.Modan M, Halkin H, Almog S, Lusky A, Eshkol M, Shitrit A,
Fuchs Z: Hyperinsulinemia: a link between hypertension,
obesity and glucose intolerance. J Clin Invest. 1985;75:809-
817.
28.Moller DE, Flier JS: Insulin resistance mechanism, syndromes
and implications. N Engl J Med. 1991;325:938-938.
29.Murad F. Nitric oxide signaling: would you believe that a
simple free radical could be a second messenger, autacoid,
paracrine substance, neurotransmitter, and hormone? Recent
progress in hormone research. 1998; 53:43-59.
30.Olefsky JM, Kolterman OG: Mechanisms of insulin resistance
in obesity and noninsulin-dependent (type II) diabetes. Am J
Med. 1981;70:151-168.
31.Olefsky JM: Insulin resistance and insulin action. An
invitro and in vivo perspective. Diabetes. 1981;30:148-162.
32.Oliver FJ, Feener EF, Lee ME, Loeken MR, Shiba T,
Quertermous T, King GL: Stimulation of endothelin-1 gene
expression by insulin in endothelial cells. J Biol Chem.
1991;266:23251-23256.
33.Porte DJ: Beta-cells in type II diabetes mellitus. Diabetes.
1991;40:166-180.
34.Prie S, Stewart DJ, Dupuis J. EndothelinA receptor blockade
improves nitric oxide-mediated vasodilation in monocrotaline-
induced pulmonary hypertension. Circulation. 1998; 97:2169-
2174.
35.Reaven GM: Role of insulin resistance in human disease.
Diabetes. 1988;37:1595-1607.
36.Rosen OM: After insulin binds. Science. 1987;237:1252-1258.
37.Sasaki A, Horiuchi N, Hasegawa K, Uehara M: Mortality and
causes of death in type 2 diabetic patients. A long-term
follow-up study in Osaka district, Japan. Diabetes Res Clin
Pract. 1989;7:33-40.
38.SimonsonMS, Dunn MJ: Endothelin. Pathways of transmembrane
signaling. Hypertension. 1990;15:I5-I12.
39.Steinberg HO, Paradisi G, Hook G, Crowder K, Cronin J, Baron
AD: Free fatty acid elevation impairs insulin-mediated
vasodilatation and nitric oxide production. Diabetes.
2000;49:1231-1238.
40.Takahashi K, Ghatei MA, Lam HC, O’Halloran DJ, Bloom SR:
Elevated plasma endothelin in patients with diabetes
mellitus. Diabetologia. 1990;33:306-310.
41.Traxinger RR, Marshall S: Glucose regulation of insulin
receptor affinity in primary cultured adipocytes. J Biol
Chem. 1990;265:18879-18883.
42.Traxinger RR, Marshall S: Recovery of maximal insulin
responsiveness and insulin sensitivity after induction of
insulin resistance in primary cultured adipocytes. J Biol
Chem. 1989;264:8156-8163.
43.Turner R, Hattersley A, Cook J: Type II diabetes: search for
primary defects. Ann Med 1992;24:511-516.
44.Yanagisawa M, Kurihara J, Kimuras S, Tomobe Y, Kobayashi M,
Mitsui Y, Yazaki Y Goto K, Masaki T: A novel potent
vasoconstrictor peptide produced by vascular endothelial
cells. Nature. 1988;332:411-415.

QRCODE
 
 
 
 
 
                                                                                                                                                                                                                                                                                                                                                                                                               
第一頁 上一頁 下一頁 最後一頁 top
系統版面圖檔 系統版面圖檔